NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Dthera™ Sciences (OTCQB: DTHR) a leading digital therapeutic company specializing in neurodegenerative diseases, today announced that its Board of Directors has initiated a process to pursue a range of potential strategic transactions to en...
SAN DIEGO, CA / ACCESSWIRE / February 25, 2019 / Dthera ™ Sciences (OTCQB: DTHR), a leading digital therapeutic company specialized in neurodegenerative diseases, is pleased to announce that it has entered into an exclusivity agreement with a company headquartered in Japan for develo...
SAN DIEGO, CA / ACCESSWIRE / February 13, 2019 / Dthera TM Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Martin Culjat, Ph.D., Senior Vice President of Scientific & Regulatory Affairs, will speak on the opening keyno...
SAN DIEGO, CA / ACCESSWIRE / February 6, 2019 / Dthera TM Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer, will be speaking at a NASA-sponsored workshop on cutting edge a...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Dthera™ Sciences (OTCQB: DTHR) a leading digital therapeutic company specializing in neurodegenerative diseases, today announced that its Board of Directors has initiated a process to pursue a range of potential strategic transactions to en...
SAN DIEGO, CA / ACCESSWIRE / February 25, 2019 / Dthera ™ Sciences (OTCQB: DTHR), a leading digital therapeutic company specialized in neurodegenerative diseases, is pleased to announce that it has entered into an exclusivity agreement with a company headquartered in Japan for develo...